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Abstract
Leber hereditary optic neuropathy (LHON) is an inherited form of bilateral optic atrophy in which the primary etiological event
is a mutation in the mitochondrial genome. The optic neuropathy involves a loss of central vision due to degeneration of the
retinal ganglion cells and optic nerve axons that subserve central vision. The primary mitochondrial mutation is necessary, but not
sufficient, for manifestation of the optic neuropathy and secondary genetic and:or epigenetic risk factors are also involved,
although they are poorly defined at the present time. There is broad agreement that mutations at nucleotides 3460, 11778 and
14484 are primary LHON mutations, but there may also be other rare primary mutations. It appears that the three primary
LHON mutations are associated with respiratory chain dysfunction, but the derangement may be relatively subtle. There is also
debate on whether there are mitochondrial mutations that have a secondary etiological or pathogenic role in LHON. The specific
pattern of neurodegeneration in LHON may arise from a ‘chokepoint’ in the optic nerve in the region of the nerve head and
lamina cribosa and which may be more severe in those LHON family members who become visually affected. It is hypothesized
that the respiratory chain dysfunction leads to axoplasmic stasis and swelling, thereby blocking ganglion cell function and causing
loss of vision. In some LHON patients, this loss of function is reversible in a substantial number of ganglion cells, but in others,
a cell death pathway (probably apoptotic) is activated with subsequent extensive degeneration of the retinal ganglion cell layer and
optic nerve. © 1998 Elsevier Science Ltd. All rights reserved.
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1. Introduction
In 1871, Theodor Leber [1] described an inherited
form of bilateral optic atrophy that has subsequently
been designated Leber hereditary optic neuropathy or
LHON (reviewed in [2–6]. It was first observed by
Leber [1] and subsequently confirmed in numerous
studies, that the risk of vision loss in LHON families is
inherited exclusively from the mother. This pattern of
maternal inheritance signifies that the primary etiologi-
cal event in LHON is a mutation within the mitochon-
drial genome (mtDNA), a unique feature among the
optic nerve degenerative disorders.
LHON involves a degeneration of the retinal gan-
glion cell layer and the accompanying axons of the
optic nerve and it is one of a group of optic neu-
ropathies. Optic nerve disease represents a major public
health issue. For example, the Baltimore eye survey
found that 5.0% of their study population suffered from
some form of optic nerve disease, 3.6% of whom had
probable or definite glaucoma and 1.4% of whom were
affected with a nonglaucomatous optic neuropathy [7].
Quigley [8] has estimated that 66 million people world-
wide are affected with glaucoma. Although LHON is a
relatively rare eye disease and its etiology is complex, it
may provide a model system for the experimental anal-
ysis of optic nerve disease. The primary mtDNA muta-
tion is necessary, but not sufficient, for the
manifestation of the optic neuropathy and secondary
etiologic factors are involved (Fig. 1). This review will
discuss the possible pathways that link the primary
LHON mutations to the ultimate end-stage, optic nerve
degeneration. Further understanding of these pathways
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Fig. 1. The etiology and natural history of LHON is complex. The primary mtDNA mutation is necessary, but not sufficient, for the optic
neuropathy and secondary etiologic factors are also involved. In addition, it is likely that the loss of vision (acute phase) results from a loss of
optic nerve function with subsequent cell death in ganglion cell layer and degeneration of the optic nerve. In a subpopulation of LHON patients,
the loss of vision is transient and there is a substantial recovery of vision. The diagram necessarily simplifies a complex biological system for
purposes of illustration. It is likely that some neurodegeneration occurs in all LHON patients (perhaps even those who subjectively perceive no
loss of vision).
in LHON should eventually define those structural or
functional sites that are the common steps in degenera-
tion of the optic nerve degeneration in a number of
disorders and which can be targeted in therapeutic
strategies.
2. Primary LHON mutations
Wallace et al. [9] showed that a mutation at mtDNA
nucleotide 11778 was a primary etiological factor in
establishing the risk of the optic neuropathy in LHON.
The 11778 primary LHON mutation changes a highly
conserved arginine residue to histidine at amino acid
position 340 (designated ND4:R340H) of the ND4
subunit of complex I (NADH-ubiquinone oxidoreduc-
tase). There is now broad agreement that sequence
changes at nucleotides 3460 (ND1:A52T) and 14484
(ND6:M64V) are also primary LHON mutations and
that these three mutations account for the vast majority
of LHON cases (reviewed in [10–14]. Mackey et al. [15]
analyzed 159 LHON families (totalling over 12000
members, more than 1400 of whom have been affected)
from Northern Europe, the United Kingdom and Aus-
tralia. It was found that 153 families (96%) carried
either the 3460 (21 families), the 11778 (109 families),
or the 14484 (23 families) primary LHON mutations.
Beyond the broad agreement about these three pri-
mary mutations, however, there is considerable debate
over the mutational spectrum of LHON. There are
reports of rare primary LHON mutations [16,17]. For
example, we have recently analyzed a Turkish LHON
family in which there is a primary LHON mutation in
the ND6 gene at nucleotide 14482 which affects the
same amino acid residue as the 14484 primary muta-
tion [18]. It has also been proposed that there are
mtDNA mutations that have an intermediate or sec-
ondary etiological role. For example, a primary role
has been proposed for a mutation at nucleotide 15257
that alters an amino acid residue (D150N) in the pro-
tonmotive cytochrome b subunit of complex III [13,14].
However, other investigators have concluded that this
sequence change is probably a benign polymorphism
[15,19]. In summary, there may be a relatively large
number of mtDNA mutations that have some role in
LHON and Brown and Wallace [10] list a total of 16
LHON mutations (their Table 1). Despite this contro-
versy, the main point is that more than 95% of all
LHON patients carry one of three mtDNA mutation
that alters a complex I subunit.
Vision loss in LHON is usually permanent, but some
patients show objective improvement, sometimes to a
dramatic degree. Recovery is rare in affected individu-
als who carry the 11778 primary mutation; for exam-
ple, Johns [13] cites a frequency of 4% (see [20] for a
well-documented case). In marked contrast, approxi-
mately one-half of all 14484 LHON patients show
recovery; the frequency of improvement is particularly
high in those who lose vision before the age of 30 years
Table 1
The ‘penetrance’ of LHON in pedigrees of Northern European origin
11 778 (%)3460 (%)Country 14 484 (%)
13NDa 8bAustralia : NZ
1830United Kingdom ND
13 14Netherlands 9
15Denmark 18 6
Finland ND ND20
ND, no data.
a Penetrance was calculated only if the total number of matrilineal
progeny was \100.
b Penetrance was calculated by summing the number of affected
males and females and then expressing this number as a percentage of
the total matrilineal progeny.
N. Howell : Vision Research 38 (1998) 1495–1504 1497
[4,13,21]. Recovery of vision in LHON patients has
important implications for a detailed understanding of
the neurodegeneration pathway, the most important
being that one must distinguish between loss of retinal
ganglion cell:optic nerve function and ganglion cell
death and optic nerve degeneration (Fig. 1).
3. The optic neuropathy in LHON
The initial symptom in LHON typically is a blurring
or clouding of vision that progresses, usually without
pain, over a period of weeks or months to its nadir.
Both eyes are often affected simultaneously and with
very rare exceptions, vision loss is bilateral. The initial
field defect is an enlargement of the blindspot that
progresses to an absolute central or cecocentral sco-
toma. Loss of visual acuity is typically severe and
complete blindness can occur; dyschromatopsia is in-
variably present. The mean age of onset is in the
mid-20’s for both sexes, although the range is remark-
ably broad, ranging from children under the age of 10
years to adults in their 70’s. An early change in the
acute phase is a pseudoedema of the nerve fiber layer
and hyperemia of the optic disk; the disk subsequently
‘flattens’ and becomes pale during the atrophic phase.
The peripapillary nerve fiber layer disappears, initially
in the papillomacular bundle. A common feature of
LHON is a peripapillary microangiopathy, first de-
scribed by Leber [1], which involves tortuous vessels in
the central retina and telangiectatic capillaries (reviewed
in [22,4,5]). The microangiopathy is present both in
presymptomatic individuals and in affected individuals
during the acute phase, but it resolves during the at-
rophic phase.
Electrophysiological studies of LHON patients have
been reviewed by Sherman and Kleiner [3]. During the
early acute phase, the visual evoked potentials (VEPs)
become desynchronized, the amplitudes are decreased
and the latencies are prolonged. At the atrophic stage,
the VEPs are almost always extinguished, which indi-
cates the loss of retinal ganglion cell function. In con-
trast, flash electroretinograms (ERG) and
electrooculograms (EOG) are normal, or nearly so,
indicating functional integrity of the photoreceptors,
bipolar cell layer and retinal pigment epithelium. A
peculiar feature of LHON is the frequent preservation
of pupillary responses [3,23,5]. The photic blink reflex is
also preserved in LHON patients, but not in non-
LHON patients with bilateral optic atrophy [24]. The
nerve fibers that control the pupillary response and the
photic blink response are thought to terminate in pre-
geniculate structures and the preferential sparing of
these pathways in LHON indicates that the optic nerve
axons which terminate in the lateral geniculate nuclei
are affected in LHON [3,24].
Several studies have addressed the neuropathology of
LHON (reviewed in [6]). Those studies were usually
performed on patients who lost vision many years prior
to death and it may be risky to extrapolate to the
neuropathological status at the time of the acute phase.
These limitations notwithstanding, LHON is consis-
tently associated with a degeneration of the ganglion
cell layer and optic nerve without signs of a marked
inflammatory process.
LHON family members can display additional ab-
normalities including peripheral neuropathy, tremor,
CNS signs and heart conduction defects [25,4,26].
There also appears to be an increased incidence of an
MS-like demyelinating disorder in LHON families, (e.g.
[27,28]). In addition to ‘classical’ LHON families, in
which the optic neuropathy is the dominant pathology,
there is a second group of families in which severe
neurological abnormalities predominate. For example,
Wallace and co-workers have analyzed ‘LHON plus
dystonia’ families who carry a pathogenic mutation at
nucleotide 14459 (ND6:A72V; [29,30]). The proximity
of this mutation to the primary LHON mutation at
nucleotide 14484 is striking. De Vries et al. [31] have
recently shown that a large Dutch family, in which the
LHON-like optic neuropathy is associated with mater-
nally transmitted hereditary spastic dystonia, carries
both a heteroplasmic mutation at nucleotide 11696
(ND4:V312I) and a homoplasmic mutation at nucle-
otide 14596 (ND6:M26I); either or both of these muta-
tions may be the primary pathogenic event. Wallace
[32] described a LHON family in which the optic
neuropathy was associated with an array of neurologi-
cal abnormalities including ataxia, dysarthria and a
juvenile onset encephalopathy. The analysis of the
mtDNA from this family suggests that the neurological
abnormalities are caused by a mutation at nucleotide
4160 which affects the ND1 subunit while the optic
neuropathy is caused by the 14484 primary LHON
mutation [11].
4. LHON and incomplete penetrance
The optic neuropathy in LHON families shows in-
complete penetrance. Historically, :50% of the males
and 10% of the females in large European LHON
families lost vision, (e.g. [22,4]). This incomplete pene-
trance indicates that, in addition to the primary
mtDNA mutation, secondary genetic and:or epigenetic
factors are necessary (Fig. 1). In :15% of LHON
patients, the primary mutation is heteroplasmic: one
mtDNA subpopulation carries the wildtype allele and
another carries the mutant allele, (e.g. [33,34]). Loss of
vision is rare unless the proportion of the primary
mutation is \75%. Heteroplasmy of the primary muta-
tion, however, cannot provide a general explanation for
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the incomplete penetrance because most LHON
families are homplasmic for the primary mutation. The
marked disparity in penetrance between males and fe-
males initially suggested an X-linked susceptibility locus
[35]. More recent studies have failed to locate such a
locus, (e.g. [36,37]) and male predominance may be due
to gender-based physiological and:or anatomical differ-
ences. Heavy alcohol and:or tobacco use increases the
risk of the optic neuropathy in LHON family members
[13,4,26], but other environmental or physiological in-
sults have also been associated with the onset of the
acute stage. One of the difficulties in ‘pinning down’ the
secondary risk factors in LHON is that it is not clear if
they act immediately prior to the onset of the acute
phase.
Johns and Berman [38] observed that sequence
changes ND1:Y304H (at nucleotide 4216), ND2:
N150D (4917) and ND5:A458T (13708) may act as
secondary LHON mutations. There is a strong associa-
tion of the 11778 and 14484 primary mutations with a
European-specific haplotype that is defined by the pres-
ence of the 4216 and 3708 secondary LHON mutations
[39,14,40]. The mtDNA haplotypes that carry the 4216,
4917, or 13708 secondary mutations form a single
monophyletic cluster and each mutation has arisen
once within this cluster [41]. Therefore, the 11778 and
14484 primary LHON mutations cannot be increasing
the frequency at which the secondary mutations arise or
are fixed within the population. Furthermore, the
11778 and 14484 primary mutations have arisen multi-
ple times within this phylogenetic cluster [41] and a
marked ‘founder’ effect is therefore an unlikely expla-
nation (see also [42]). These secondary mutations may
increase the penetrance of the optic neuropathy [14,42].
Among 11778 Australian LHON families, the pene-
trance of the optic neuropathy was higher in families
whose mitochondrial genomes carry the 4216 and
13708 secondary LHON mutations than in those who
do not [43], but other studies have found no pathogenic
effect of these secondary mutations [19]. It is also
possible that primary LHON mutations arise and:or
fixed more frequently in the 4216:13708 mtDNA
haplotype.
The hypothesis that penetrance in LHON pedigrees
is a function of the mtDNA haplotype may be ex-
tremely difficult to test because penetrance is sensitive
to a number of poorly defined factors. The results in
Table 1 summarize the extensive data of Mackey et al.
[15]. For each of the three primary mutations, pene-
trance varies more than 2-fold among different study
populations. Penetrance is difficult to measure accu-
rately because of the marked variability in age of onset
among individuals and the values in Table 1 were
derived by simply dividing the number of affected
individuals by the total number of matrilineal progeny.
Furthermore, simple classification into ‘affected’ and
‘non-affected’ may be misleading because there are
LHON family members who report no vision problems
but who have objective signs of optic neuropathy, (e.g.
[18]). The overall penetrance in Australian LHON
families has been decreasing during this century, appar-
ently in parallel with the declining incidence of tobacco
amblyopia, a result suggesting a common etiological
factor [44]. Finally, even within single LHON pedigrees
in which the family members live in a fairly restricted
geographical distribution, there are matrilineal
branches in which penetrance has dropped, essentially,
to zero. These ‘low penetrance’ branches are not due to
reversion or segregational loss of the primary LHON
mutation (Mackey and Howell, manuscript in
preparation).
5. Mitochondrial respiratory chain dysfunction in
LHON
It seems obvious that, because LHON mutations
alter complex I subunits, the clinical defects result from
respiratory chain dysfunction. However, such a
straightforward association has been difficult to prove.
Larsson et al. [45] isolated mitochondria from affected
and unaffected members of an 11778 LHON family
and they found no decrease in complex I specific activ-
ity (or in any other respiratory chain complex). On the
other hand, flux through the entire chain with NADH-
linked substrates was decreased to about one-half of the
values found in mitochondria from normal controls.
There was no decrease in flux with succinate as sub-
strate, which enters the chain through complex II. The
authors suggested that complex I function was impaired
in its association with the proximal dehydrogenases.
Essentially the same results were obtained by Majander
et al. [46] in studies with EB-virus transformed
lymphocytes from 11778 LHON patients. Smith et al.
[47] detected a small decrease (25%) in platelet mito-
chondrial complex I specific activity when non-smoking
11778 LHON patients were compared to non-smoking
controls; no difference was found when smokers were
included in the two groups. Vergani et al. [48] have
constructed cybrid lines in which mitochondria from
control or 11778 LHON patients were transferred to
cells that lack their own mtDNA (designated rho-zero
lines). The 11778 primary LHON mutation caused
decreased cellular respiration and lower mitochondrial
complex I specific activity, although the latter decrease
was not statistically significant. Similarly, there was a
40% decrease in mitochondrial respiration with
NADH-linked substrates in another set of 11778 cybrid
lines, although there was no decrease in complex I
specific activity [49].
Degli Esposti et al. [50] also found that complex I
activity in platelet mitochondria of 11778 LHON pa-
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tients was not decreased, but-more importantly-they
observed increased resistance to rotenone, as well as
changes in the affinity of the complex for ubiquinone
substrate analogs. They suggested that the arginine
residue that is altered by the 11778 LHON mutation
occurs in a region of the ND4 subunit which is involved
in quinone reduction and that the substitution with
histidine may result in decreased stability of the
semiquinone intermediate during redox catalysis. They
further speculated that this catalytic ‘short circuit’ in
their terminology may not decrease complex I turnover,
but that it could decrease the oxidation rates of
NADH-linked substrates because of lowered ubiquinol
production (see also the additional studies in [51]).
The results for the 3460 primary mutation have been
more clear-cut. In our initial studies [52], platelet mito-
chondria were isolated from 3460 LHON family mem-
bers. When specific activities of the respiratory chain
complexes were normalized to the specific activity of
mitochondrial citrate synthase, there was :80% reduc-
tion in complex I specific activity, whereas there was no
reduction in those of complex II or complex IV (cy-
tochrome oxidase). The complex I dysfunction was
equally severe in both affected and unaffected LHON
family members and in both males and females [52].
Similar results were obtained by Majander et al. [46],
Smith et al. [47] and Carelli et al. [51].
The reported effects of the 14484 primary LHON
mutation upon respiratory chain function have been
contradictory. Parker et al. [53] measured an :80%
reduction in complex I specific activity in platelet mito-
chondria from QLD1 LHON patients. The interpreta-
tion of these results, however, is complicated by the
simultaneous presence of the 14484 LHON and 4160
mutations (see above). Cock et al. [54] found no res-
piratory chain dysfunction in fibroblast mitochondria
from ‘14484 only’ LHON patients. Other studies, in
contrast, indicate a marked complex I defect in 14484
fibroblast mitochondria (Bindoff, personal communica-
tion; [55]). Jun et al. [30] have analyzed respiratory
chain function in mitochondria from both EBV-trans-
formed lymphoblast lines and transmitochondrial
lymphoblast lines from patients with the 14459 ‘LHON
plus dystonia’ mutation. Complex I specific activities
were reduced by :50%, but there is no reduction in
mitochondrial respiration with either NADH-linked
substrates or with succinate (the inverse pattern that is
seen for the 11778 primary LHON pattern).
We have measured the release of lactate and pyruvate
from intact, dividing fibroblasts in an effort to avoid
the problems that are associated with isolation of mito-
chondria and the assay of respiratory chain function.
The lactate:pyruvate ratio is a sensitive indicator of the
NADH:NAD balance and it will be, in large part, ‘set’
by flux through the mitochondrial respiratory chain.
When the respiratory chain is blocked, the NADH
generated by the citric acid cycle and glycolysis accu-
mulates and the lactate:pyruvate ratio increases. Our
preliminary results indicate that all three primary
LHON mutations are associated with mitochondrial
respiratory chain dysfunction, although the defect asso-
ciated with the 11778 mutation appears to be less
severe (Howell et al., manuscript in preparation). It is
possible that mitochondrial function in the ganglion cell
layer may be necessary to maintain the proper NAD:
NADH redox balance, rather than for ATP biosynthe-
sis per se, because complex I is the site of NADH
reoxidation. Taken together, the biochemical studies
are paradoxical because the 11778 primary mutation is
the most severe in terms of the optic neuropathy, but
apparently the least severe in terms of the severity of
the respiratory chain defect. One must be cautious in
the interpretation of these biochemical studies, not least
because they utilized cell types that are not those patho-
logically affected.
The causal relationship between mitochondrial muta-
tions and a focal degeneration of the ganglion cell layer
and optic nerve suggests that LHON involves neurode-
generation of those cells (viz., retinal ganglion cells)
that have the highest demand for mitochondrially-pro-
duced energy, (e.g. [56,57]). In fact, however, it has
been recognized for 40 years that the photoreceptor
layer of the retina is the richest in the enzymes of
oxidative metabolism [58]. Furthermore, Ames et al.
[59] showed that phototransduction in the rabbit retina
was dependent upon energy generated by the mitochon-
drial respiratory chain, whereas neurotransmission
through the inner retina was fueled predominantly by
glycolysis (also, see [60]). It appears more likely, there-
fore, that the retinal ganglion cell layer and optic nerve
are selectively affected in LHON, not because they have
the highest overall oxidative demand, but because they
are the most susceptible to disruption of complex I at a
specific point in the vision pathway, metabolic and:or
anatomical (see below). There is a ‘forgotten’ set of
studies that support this distinction.
In the 1950’s and 1960’s, the antibiotic chloram-
phenicol was used to treat children with cystic fibrosis
[61], but this treatment caused an optic atrophy [62–
64]. In a presentation that was remarkably similar to
LHON, there was a sudden onset, bilateral loss of
central vision with the formation of central scotomata;
papilloedema and subsequent pallor of the disk were
also documented. There was also an engorgement and
tortuosity of the retinal veins with occasional retinal
hemorrhage. Neuropathological studies revealed degen-
eration in the ganglion cell layer, degeneration and
demyelination of the optic nerve (particularly in the
papillomacular bundle) and gliosis of the nerve fiber
layer [64]. The use of chloramphenicol in cystic fibrosis
patients was undertaken before it was recognized that
this antibiotic is a specific inhibitor of mitochondrial
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Fig. 2. A proposed biochemical scheme for the optic neuropathy in LHON. The figure shows one possible pathway of the early steps that link
the primary LHON mutations and the degeneration of the optic nerve (see text for detailed discussion). There appear to be several different
apoptotic pathways and the one shown here is based upon studies in neuronal systems. In addition, the different steps shown may occur
simultaneously.
protein synthesis. The characteristics of this optic neu-
ropathy provide the strongest and most direct evidence
that the human ganglion cell layer and optic nerve are
exquisitely sensitive to the disruption of mitochondrial
biogenesis.
6. Models for optic nerve degeneration in LHON
At the present time, much is known about the genetic
basis of LHON and progress is being made on the
biochemical analysis of the respiratory chain defects.
However, relatively little is known about the pathway
that connects the respiratory chain dysfunction to loss
of vision and neurodegeneration. For the purposes of
stimulating further discussion and experimentation, one
possible pathway is shown in Fig. 2. There are studies
on the microanatomy and histochemistry of the retina
and optic nerve, that may explain, at least in part, the
selective involvement of the ganglion cell layer and
optic nerve in LHON. Burde [65] has developed the
‘disk at risk’ concept in which he identified the anatom-
ical features that are common to several optic neu-
ropathies including LHON: a relatively small optic
nerve head, absent or small cup, increased branching of
the central retinal vessels within the disk and a crowd-
ing or ‘heaping up’ of the nerve fiber layer. He further
postulated that the region in and around the lamina
cribosa is particularly vulnerable to ischemia (complex I
dysfunction in LHON) because of the limited vascular-
ization. The septae of the lamina cribosa are more
closely packed and thicker walled along the horizontal
meridian of the optic nerve [66] and these are the
‘channels’ for the nerve fibers that subserve the central
and temporal portion of the visual field, which are the
areas most severely affected in LHON (also, see [2]).
Significantly, there is an accumulation of mitochondria
in the unmyelinated segments of the prelamellar optic
nerve axons before they transverse the lamina cribosa
[67,68]. This accumulation of mitochondria indicates
impaired or labile axoplasmic transport, a ‘chokepoint’,
in this region of the optic nerve. Kageyama and Wong-
Riley [67] showed that parafoveal ganglion cells in the
monkey retina are less intensely stained for cytochrome
oxidase than those in the periphery and that the larger
ganglion cells tended to be more intensely stained than
those of medium and small size. Their results suggest
that parafoveal ganglion cells may be ‘poorer’ in mito-
chondrial content and thereby more susceptible to dis-
ruption of the respiratory chain in the chokepoint.
One can thus envisage that the primary LHON muta-
tion produces a respiratory chain defect that compro-
mises axoplasmic transport and which results in axon
swelling and compression of the vessels and nerve
fibers, particularly in the lamina cribosa ‘chokepoint’,
but not so severely that there is a frank loss of retinal
ganglion cell function (Fig. 1). Further physiological or
environmental stress, particularly in those individuals
that are anatomically ‘vulnerable’, triggers a more pro-
found slowing of axoplasmic transport to a level that
precludes normal functioning of the smaller diameter
ganglion cells [65]. According to this hypothetical
scheme, the peripapillary microangiopathy in presymp-
tomatic LHON patients may be a secondary conse-
quence of the swelling of the optic nerve axons in the
anatomically constricted chokepoint and which resolves
during the acute phase because the neurodegeneration
relieves the crowding in this region. Riordan-Eva et al.
[4] have proposed that the LHON family members who
become visually affected may have congenital crowding
of the ganglion cell axons at the disk and in the
peripapillary region, leading to the preferential degener-
ation of the smaller diameter M and P ganglion cells.
The respiratory chain dysfunction in LHON may
cause ganglion cell and axon swelling through a path-
way that activates the mitochondrial permeability tran-
sition and activation of the redox-sensitive NMDA
(N-methyl-D-aspartate) channel (Fig. 1). Apoptosis is
usually triggered by some ‘external’ signal; in nerve
cells, for example, by excitotoxic levels of glutamate.
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There is accumulating evidence that opening of the
mitochondrial transition pore and of the NMDA chan-
nel are early steps in apoptotic pathways [69–71]. Sku-
lachev [72] has proposed that the mitochondrial
permeability transition is triggered by the build-up of
reactive oxygen species, particularly superoxide anion
which can result from respiratory chain dysfunction.
Exposure of neurons in culture to NMDA caused an
increase in mitochondrial ROS production, probably as
a consequence of uncoupling of the respiratory chain
[73]. It has been shown that rotenone, a Complex I
inhibitor, induces apoptosis in some cell lines [74,75].
Complex I is a key site for free radical formation and it
is striking that the three most prevalent primary LHON
mutations affect Complex I subunits. In LHON, the
apoptotic cascade apparently runs ‘in reverse’ because
the initial signal is internal (respiratory chain dysfunc-
tion), not external.
Although it has not been demonstrated directly, neu-
rodegeneration of the ganglion cell layer and optic
nerve in LHON probably occurs through apoptosis,
rather than necrosis (Fig. 2). In the first place, the
neurodegeneration in LHON has never been associated
with the overt signs of inflammation, which accompa-
nies necrosis but is not observed in apoptotic cell death.
Secondly, ganglion cell apoptosis has been observed in
a wide variety of conditions. (1) During development,
the number of retinal ganglion cells is more than twice
the number found in the adult retina. The ‘extra’
ganglion cells die through a pathway that has the
morphological features of apoptosis and which is pre-
vented by overexpression of the anti-apoptotic bcl-2
protein [76]. (2) Apoptosis in induced by optic nerve
axotomy in rodents, but degeneration of the ganglion
cell layer is ameliorated by overexpression of bcl-2
[77,78]. (3) Quigley et al. [79] have reported that gan-
glion cell death in experimental glaucoma occurs by
apoptosis. Significantly, there is also considerable evi-
dence that an excitotoxic pathway ‘triggers’ the optic
nerve degeneration in glaucoma [80,81]. (4) Levin and
Louhab [82] have described a patient with anterior
ischemic optic neuropathy in which there were morpho-
logical signs of apoptosis in the ganglion cell layer. The
apparent involvement of bcl-2 in regulation of apopto-
sis in the ganglion cell layer is intriguing and it suggests
another possible step in LHON neurodegeneration. It
has recently been shown that release of mitochondrial
cytochrome c is involved at an early step in apoptosis,
prior to caspase activation and that bcl-2-which is
associated with mitochondria-prevents its release
[83,84]. It is attractive to suggest that the respiratory
chain dysfunction in LHON can initiate a pathway that
involves mitochondrial swelling and release of cy-
tochrome c, which ultimately triggers apoptosis. One
must be cautious, however, because there may be multi-
ple apoptotic pathways. Thus, Susin et al. [85] have
described a cell system in which bcl-2 blocks apoptosis
through inhibition of the release of a 50 K apoptosis-in-
ducing factor (AIF) from mitochondria.
In the case of the 11778 primary mutation, for
reasons which are not yet known, the ‘commitment to
death’ is made with only rare exception. At the oppo-
site extreme, the commitment to death is much less
strong or less frequent for the 14484 primary mutation
and a substantial proportion of the retinal ganglion
cells can remain inactive but viable for prolonged peri-
ods of time. It is important to stress that the neurode-
generation is not an ‘all-or-none’ phenomenon and that
it is the extent of ganglion cell death that varies. If this
hypothesis is correct, recovery of vision in 14484
LHON patients might occur as the result of a small
amount of neurodegeneration, thus reversing the
anatomical block to axoplasmic transport in the viable-
but-inactive neurons. This suggested mechanism can
also explain the peak incidence of LHON in the mid-
20’s: starting in the second decade, there is a slow loss
of foveal ganglion cells [86], thus widening the choke-
point and commensurately diminishing the subsequent
risk of vision loss.
Further investigation will elucidate the intermediate
steps between the primary LHON mutations and end-
point of retinal ganglion cell and optic nerve neurode-
generation. This additional information will
undoubtedly provide many fundamental insights, but-
more importantly, it will allow the development of
therapeutic strategies to prevent or minimize the devas-
tating ophthalmological consequences of these mito-
chondrial mutations.
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